Madrigal Pharmaceuticals Clinical Trials: 18 Led Studies

Archive historyOct 2022 to Jun 2026

29 recorded changes across Madrigal Pharmaceuticals trials

Every status move, completion date shift and enrollment change ComplyRx has recorded across 8 of these trials. One is shown below.

Completion date movePrimary completion moved 365 days laterNCT04951219 · recorded 1 Jun 2026

Track to read them

+25 more recorded changes · Track a drug to see every change the night it lands

Track resmetirom

Most active programmes

The drugs appearing most often across Madrigal Pharmaceuticals's recently active trials. Comparator arms are excluded.

MGL-31968 trials
Resmetirom4 trials
VIA-31962 trials
Resmetirom1 trial
Liver Biopsy1 trial
Rezdiffra1 trial

Upcoming readouts

Next primary completion dates among Madrigal Pharmaceuticals's active phase 2 and phase 3 trials. Dates are registry estimates and move often, which is exactly what the tracker watches.

Aug 2028Study to Evaluate Resmetirom in Post-Liver Transplant Patients With MASHPhase 2

Top therapeutic areas

Conditions studied most often across Madrigal Pharmaceuticals's recently active trials.

Cirrhosis, Liver2 trials
MASH - Metabolic Dysfunction-Associated Steatohepatitis2 trials
NASH - Nonalcoholic Steatohepatitis2 trials
Non-Alcoholic Fatty Liver Disease2 trials
Drug Safety2 trials
NASH1 trial

Madrigal Pharmaceuticals trials

The 18 most significant of Madrigal Pharmaceuticals's recently active trials, soonest estimated readout first.
Select any row for the full record; the change timeline unlocks with tracking.

Trial	Phase	Stability	Status	Enrollment	Est. readout
A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)NCT05500222Resmetirom	Phase 3	Locked · track to reveal	OngoingActive, not recruiting	845 est.	Dec 2026
A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)NCT04951219Resmetirom	Phase 3	Locked · track to reveal	OngoingActive, not recruiting	810 est.	Mar 2027
MAESTRO-NASHA Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and FibrosisNCT03900429MGL-3196	Phase 3	Locked · track to reveal	OngoingActive, not recruiting	1,759 est.	Jan 2028
Study to Evaluate Resmetirom in Post-Liver Transplant Patients With MASHNCT07335601Resmetirom	Phase 2	Locked · track to reveal	OngoingRecruiting	120 est.	Aug 2028
Rezdiffra Pregnancy and Lactation RegistryNCT07541469Rezdiffra	—	Locked · track to reveal	OngoingRecruiting	10 est.	8 Apr 2030
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses (6 Days) of 100 mg Resmetirom in Subjects With Severe Renal Impairment and in Matched Healthy Control Subjects With Normal Renal FunctionNCT06397872100 mg Resmetirom Tablet	Phase 1	Locked · track to reveal	Completed	28 est.	16 Sept 2024
MAESTRO-NAFLD1A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Non Alcoholic Fatty Liver Disease PatientsNCT04197479Resmetirom	Phase 3	Locked · track to reveal	Completed	1,343 est.	6 Jan 2023
Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses of MGL-3196 in Subjects With Varying Degrees of Hepatic Impairment and Healthy Matched Control SubjectsNCT04643795MGL-3196	Phase 1	Locked · track to reveal	Completed	87 est.	4 Aug 2021
Drug Interaction Study of MGL-3196 With ClopidogrelNCT04671069MGL-3196	Phase 1	Locked · track to reveal	Completed	20 est.	30 Aug 2019
Drug Interaction Study of MGL-3196 With PioglitazoneNCT04671056MGL-3196	Phase 1	Locked · track to reveal	Completed	16 est.	11 Dec 2018
Bioavailability Study of MGL-3196 Tablets Compared to CapsulesNCT03413124MGL-3196 Tablet	Phase 1	Locked · track to reveal	Completed	16 est.	17 Feb 2018
Study of MGL-3196 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH)NCT03038022MGL-3196 (resmetirom)	Phase 2	Locked · track to reveal	Completed	116 est.	15 Jan 2018
Phase 2 Study of MGL-3196 in Patients With Non-Alcoholic Steatohepatitis (NASH)NCT02912260MGL-3196	Phase 2	Locked · track to reveal	Completed	125 est.	25 Oct 2017
Radiolabeled Study to Determine the Mass Balance of [14C] MGL-3196NCT03220165MGL-3196	Phase 1	Locked · track to reveal	Completed	8 est.	3 Sept 2017
Drug Interaction Study of MGL-3196 With AtorvastatinNCT02749578Atorvastatin	Phase 1	Locked · track to reveal	Completed	14 est.	May 2016
Drug Interaction Study of MGL-3196 With Rosuvastatin and SimvastatinNCT02542969Simvastatin	Phase 1	Locked · track to reveal	Completed	25 est.	Oct 2015
Ascending Multiple-Dose Study to Evaluate VIA-3196 in Healthy SubjectsNCT01519531VIA-3196	Phase 1	Locked · track to reveal	Completed	48 est.	Nov 2012
Ascending Single-Dose Study to Evaluate VIA-3196 in Healthy SubjectsNCT01367873VIA-3196	Phase 1	Locked · track to reveal	Completed	72 est.	Oct 2011

View all trials18

A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)

Phase 3Active, not recruitingNCT05500222 ↗

Primary completion: Dec 2026; estimated
Enrollment: 845; estimated
Start: Aug 2022; Madrigal Pharmaceuticals, Inc.

Conditions

NASH
Cirrhosis, Liver

Interventions

Resmetirom
Placebo

Brief summary

This study will determine the effect of oral 80 mg resmetirom administered once daily on participants with well-compensated non-alcoholic steatohepatitis (NASH) cirrhosis by measuring the time to experiencing a Composite Clinical Outcome event.

Full record on ClinicalTrials.gov ↗

Change timeline

2 recorded · latest 1 Jul 2025

Status change · 1

Completion date move · 1

Track Madrigal Pharmaceuticals drugs to see every change the night it lands.

Track resmetirom

A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)

Phase 3Active, not recruitingNCT04951219 ↗

Primary completion: Mar 2027; estimated
Enrollment: 810; estimated
Start: Jul 2021; Madrigal Pharmaceuticals, Inc.

Conditions

Non-Alcoholic Fatty Liver Disease

Interventions

Resmetirom

Brief summary

A 52-Week, Multi-center, Open-label, Active Treatment Extension Study to Evaluate Safety and Tolerability of Once Daily, Oral Administration of Resmetirom (MGL-3196)

Full record on ClinicalTrials.gov ↗

Change timeline

5 recorded · latest 1 Jun 2026

Completion date move · 3

Enrollment change · 1

Status change · 1

Track Madrigal Pharmaceuticals drugs to see every change the night it lands.

Track resmetirom

MAESTRO-NASH: A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis

Phase 3Active, not recruitingNCT03900429 ↗

Primary completion: Jan 2028; estimated
Enrollment: 1,759; estimated
Start: Mar 2019; Madrigal Pharmaceuticals, Inc.

Conditions

NASH - Nonalcoholic Steatohepatitis

Interventions

MGL-3196
Placebo
Liver Biopsy

Brief summary

A double-blind placebo controlled randomized Phase 3 study to determine if 80 or 100 mg of MGL-3196 as compared with placebo resolves NASH and/or reduces fibrosis on liver biopsy and prevents progression to cirrhosis and/or advanced liver disease

Full record on ClinicalTrials.gov ↗

Change timeline

5 recorded · latest 1 Apr 2024

Completion date move · 3

Enrollment change · 1

Status change · 1

Track Madrigal Pharmaceuticals drugs to see every change the night it lands.

Track resmetirom

Study to Evaluate Resmetirom in Post-Liver Transplant Patients With MASH

Phase 2RecruitingNCT07335601 ↗

Primary completion: Aug 2028; estimated
Enrollment: 120; estimated
Start: Dec 2025; Madrigal Pharmaceuticals, Inc.

Conditions

MASH - Metabolic Dysfunction-Associated Steatohepatitis

Interventions

Resmetirom
Placebo

Brief summary

A Phase 2 double-blind, randomized, placebo-controlled study to evaluate resmetirom in 2 cohorts of subjects with moderate to advanced fibrosis, consistent with stage F2 and F3 fibrosis, who have undergone liver transplant. Cohort 1 will consist of patients who have undergone liver transplant for MASH cirrhosis who…

Full record on ClinicalTrials.gov ↗

Change timeline

2 recorded · latest 1 Jun 2026

Completion date move · 1

Status change · 1

Track Madrigal Pharmaceuticals drugs to see every change the night it lands.

Track resmetirom

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses (6 Days) of 100 mg Resmetirom in Subjects With Severe Renal Impairment and in Matched Healthy Control Subjects With Normal Renal Function

Phase 1CompletedNCT06397872 ↗

Primary completion: Sept 2024; actual
Enrollment: 28; estimated
Start: Mar 2024; Madrigal Pharmaceuticals, Inc.

Conditions

Renal Impairment

Interventions

100 mg Resmetirom Tablet

Brief summary

The purpose of this study is to directly characterize the pharmacokinetic (PK) profiles of resmetirom and its major metabolite (MGL-3623) following oral administration of 100 mg resmetirom (QD x 6 days) in subjects with severe renal impairment (RI) compared to healthy matched control subjects with normal renal…

Full record on ClinicalTrials.gov ↗

Change timeline

3 recorded · latest 1 Nov 2025

Completion date move · 1

Status change · 1

Enrollment change · 1

Track Madrigal Pharmaceuticals drugs to see every change the night it lands.

Track resmetirom

MAESTRO-NAFLD1: A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Non Alcoholic Fatty Liver Disease Patients

Phase 3CompletedNCT04197479 ↗

Primary completion: Jan 2023; actual
Enrollment: 1,343; estimated
Start: Dec 2019; Madrigal Pharmaceuticals, Inc.

Conditions

Non-Alcoholic Fatty Liver Disease

Interventions

Placebo
Resmetirom

Brief summary

A double-blind placebo controlled randomized Phase 3 study to evaluate the safety and tolerability of once-daily, oral administration of 80 or 100 mg resmetirom versus matching placebo. At least 100 patients will be enrolled in a 100 mg open-label arm and will include a special safety population (eg, patients with…

Full record on ClinicalTrials.gov ↗

Change timeline

6 recorded · latest 1 Oct 2023

Completion date move · 2

Enrollment change · 2

Status change · 2

Track Madrigal Pharmaceuticals drugs to see every change the night it lands.

Track resmetirom

Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses of MGL-3196 in Subjects With Varying Degrees of Hepatic Impairment and Healthy Matched Control Subjects

Phase 1CompletedNCT04643795 ↗

Primary completion: Aug 2021; actual
Enrollment: 87; estimated
Start: Oct 2018; Madrigal Pharmaceuticals, Inc.

Conditions

Hepatic Impairment
NASH - Nonalcoholic Steatohepatitis
Cirrhosis, Liver

Interventions

MGL-3196

Brief summary

The purpose of this study is to directly characterize the pharmacokinetic (PK) profiles of MGL-3196 and its major metabolite (MGL-3623) following administration of multiple oral doses (QD x 6 days) in subjects with varying degrees of hepatic impairment (HI) compared to healthy matched control subjects with normal…

Full record on ClinicalTrials.gov ↗

Change timeline

4 recorded · latest 1 Jan 2024

Status change · 2

Completion date move · 1

Enrollment change · 1

Track Madrigal Pharmaceuticals drugs to see every change the night it lands.

Track resmetirom